secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2023-02-02T23:59:59+00:00
Accession:  0001193125-23-022825
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Magenta Therapeutics halts all programs, explores strategic alternatives
------------------------------------------------------------------------

- Halts all development programs; will explore strategic alternatives including acquisition, merger, or business combination.
- Received Nasdaq deficiency notice for common stock bid price below $1.00 for 30 consecutive trading days.
- Has 180 days (until July 31, 2023) to regain compliance with minimum bid price requirement.
- No timetable set for strategic review; no assurance a transaction will be completed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/0001193125-23-022825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000119312523022825/d445995d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-022825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer